Baseline endometriosis-associated pain burden: Data from 1600+ women enrolled in elagolix clinical trials

Nicholas Leyland, Stephanie Estes, Samantha Eichner, Ahmed M. Soliman, Yabing Mai, Michael C. Snabes, Hugh S. Taylor, Eric S. Surrey

Research output: Contribution to journalArticle

Abstract

Background: The daily pain burden experienced by women with endometriosis has not been well studied. Objective: To characterize baseline pain among women with moderate-to-severe endometriosis-associated pain enrolled in phase 3 studies of elagolix, an oral, nonpeptide gonadotropin-releasing hormone antagonist. Study design: Data were pooled from the screening phase of two randomized, double-blind, placebo-controlled clinical trials. After cessation of endometriosis medications, patients entered the screening phase during which symptoms (dysmenorrhea, nonmenstrual pelvic pain, and dyspareunia) and rescue medication use were recorded daily in electronic diaries. Endometriosis-associated pain was also scored using the Numeric Rating Scale (range 0–10). Baseline was defined as the last 35 days during the screening period. Results: Endometriosis-associated pain was reported by the 1686 study participants on most days during the baseline interval. Pain was often moderate or severe, with a mean Numeric Rating Scale score of 5.6 ± 1.7. Women reported dysmenorrhea an average of 8.1 ± 3.0 days (97.9% ± 7.0% of menstruating days), nonmenstrual pelvic pain on 20.5 ± 5.4 days (90.3% ± 15.8% of nonmenstruating days), and dyspareunia on 8.7 ± 8.0 days (81.7% ± 29.7% of sexually active days). When they occurred, dysmenorrhea, nonmenstrual pelvic pain, and dyspareunia were frequently moderate or severe in intensity. Women were free of pelvic pain for an average of 2.4 ± 3.9 days during the 35-day evaluation interval. Conclusion: Among women with untreated moderate-to-severe endometriosis pain, the daily burden of pain was extensive, both during menstruation and on nonmenstruating days.

Original languageEnglish (US)
Pages (from-to)117-125
Number of pages9
JournalJournal of Endometriosis and Pelvic Pain Disorders
Volume11
Issue number3
DOIs
StatePublished - Sep 1 2019

Fingerprint

Endometriosis
Clinical Trials
Pain
Pelvic Pain
Dyspareunia
Dysmenorrhea
Hormone Antagonists
Menstruation
elagolix
Controlled Clinical Trials
Gonadotropin-Releasing Hormone
Placebos

All Science Journal Classification (ASJC) codes

  • Obstetrics and Gynecology

Cite this

Leyland, Nicholas ; Estes, Stephanie ; Eichner, Samantha ; Soliman, Ahmed M. ; Mai, Yabing ; Snabes, Michael C. ; Taylor, Hugh S. ; Surrey, Eric S. / Baseline endometriosis-associated pain burden : Data from 1600+ women enrolled in elagolix clinical trials. In: Journal of Endometriosis and Pelvic Pain Disorders. 2019 ; Vol. 11, No. 3. pp. 117-125.
@article{01f5420ac9a349a495bd89301665ba79,
title = "Baseline endometriosis-associated pain burden: Data from 1600+ women enrolled in elagolix clinical trials",
abstract = "Background: The daily pain burden experienced by women with endometriosis has not been well studied. Objective: To characterize baseline pain among women with moderate-to-severe endometriosis-associated pain enrolled in phase 3 studies of elagolix, an oral, nonpeptide gonadotropin-releasing hormone antagonist. Study design: Data were pooled from the screening phase of two randomized, double-blind, placebo-controlled clinical trials. After cessation of endometriosis medications, patients entered the screening phase during which symptoms (dysmenorrhea, nonmenstrual pelvic pain, and dyspareunia) and rescue medication use were recorded daily in electronic diaries. Endometriosis-associated pain was also scored using the Numeric Rating Scale (range 0–10). Baseline was defined as the last 35 days during the screening period. Results: Endometriosis-associated pain was reported by the 1686 study participants on most days during the baseline interval. Pain was often moderate or severe, with a mean Numeric Rating Scale score of 5.6 ± 1.7. Women reported dysmenorrhea an average of 8.1 ± 3.0 days (97.9{\%} ± 7.0{\%} of menstruating days), nonmenstrual pelvic pain on 20.5 ± 5.4 days (90.3{\%} ± 15.8{\%} of nonmenstruating days), and dyspareunia on 8.7 ± 8.0 days (81.7{\%} ± 29.7{\%} of sexually active days). When they occurred, dysmenorrhea, nonmenstrual pelvic pain, and dyspareunia were frequently moderate or severe in intensity. Women were free of pelvic pain for an average of 2.4 ± 3.9 days during the 35-day evaluation interval. Conclusion: Among women with untreated moderate-to-severe endometriosis pain, the daily burden of pain was extensive, both during menstruation and on nonmenstruating days.",
author = "Nicholas Leyland and Stephanie Estes and Samantha Eichner and Soliman, {Ahmed M.} and Yabing Mai and Snabes, {Michael C.} and Taylor, {Hugh S.} and Surrey, {Eric S.}",
year = "2019",
month = "9",
day = "1",
doi = "10.1177/2284026519864232",
language = "English (US)",
volume = "11",
pages = "117--125",
journal = "Journal of Endometriosis",
issn = "2035-9969",
publisher = "Wichtig Publishing",
number = "3",

}

Baseline endometriosis-associated pain burden : Data from 1600+ women enrolled in elagolix clinical trials. / Leyland, Nicholas; Estes, Stephanie; Eichner, Samantha; Soliman, Ahmed M.; Mai, Yabing; Snabes, Michael C.; Taylor, Hugh S.; Surrey, Eric S.

In: Journal of Endometriosis and Pelvic Pain Disorders, Vol. 11, No. 3, 01.09.2019, p. 117-125.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Baseline endometriosis-associated pain burden

T2 - Data from 1600+ women enrolled in elagolix clinical trials

AU - Leyland, Nicholas

AU - Estes, Stephanie

AU - Eichner, Samantha

AU - Soliman, Ahmed M.

AU - Mai, Yabing

AU - Snabes, Michael C.

AU - Taylor, Hugh S.

AU - Surrey, Eric S.

PY - 2019/9/1

Y1 - 2019/9/1

N2 - Background: The daily pain burden experienced by women with endometriosis has not been well studied. Objective: To characterize baseline pain among women with moderate-to-severe endometriosis-associated pain enrolled in phase 3 studies of elagolix, an oral, nonpeptide gonadotropin-releasing hormone antagonist. Study design: Data were pooled from the screening phase of two randomized, double-blind, placebo-controlled clinical trials. After cessation of endometriosis medications, patients entered the screening phase during which symptoms (dysmenorrhea, nonmenstrual pelvic pain, and dyspareunia) and rescue medication use were recorded daily in electronic diaries. Endometriosis-associated pain was also scored using the Numeric Rating Scale (range 0–10). Baseline was defined as the last 35 days during the screening period. Results: Endometriosis-associated pain was reported by the 1686 study participants on most days during the baseline interval. Pain was often moderate or severe, with a mean Numeric Rating Scale score of 5.6 ± 1.7. Women reported dysmenorrhea an average of 8.1 ± 3.0 days (97.9% ± 7.0% of menstruating days), nonmenstrual pelvic pain on 20.5 ± 5.4 days (90.3% ± 15.8% of nonmenstruating days), and dyspareunia on 8.7 ± 8.0 days (81.7% ± 29.7% of sexually active days). When they occurred, dysmenorrhea, nonmenstrual pelvic pain, and dyspareunia were frequently moderate or severe in intensity. Women were free of pelvic pain for an average of 2.4 ± 3.9 days during the 35-day evaluation interval. Conclusion: Among women with untreated moderate-to-severe endometriosis pain, the daily burden of pain was extensive, both during menstruation and on nonmenstruating days.

AB - Background: The daily pain burden experienced by women with endometriosis has not been well studied. Objective: To characterize baseline pain among women with moderate-to-severe endometriosis-associated pain enrolled in phase 3 studies of elagolix, an oral, nonpeptide gonadotropin-releasing hormone antagonist. Study design: Data were pooled from the screening phase of two randomized, double-blind, placebo-controlled clinical trials. After cessation of endometriosis medications, patients entered the screening phase during which symptoms (dysmenorrhea, nonmenstrual pelvic pain, and dyspareunia) and rescue medication use were recorded daily in electronic diaries. Endometriosis-associated pain was also scored using the Numeric Rating Scale (range 0–10). Baseline was defined as the last 35 days during the screening period. Results: Endometriosis-associated pain was reported by the 1686 study participants on most days during the baseline interval. Pain was often moderate or severe, with a mean Numeric Rating Scale score of 5.6 ± 1.7. Women reported dysmenorrhea an average of 8.1 ± 3.0 days (97.9% ± 7.0% of menstruating days), nonmenstrual pelvic pain on 20.5 ± 5.4 days (90.3% ± 15.8% of nonmenstruating days), and dyspareunia on 8.7 ± 8.0 days (81.7% ± 29.7% of sexually active days). When they occurred, dysmenorrhea, nonmenstrual pelvic pain, and dyspareunia were frequently moderate or severe in intensity. Women were free of pelvic pain for an average of 2.4 ± 3.9 days during the 35-day evaluation interval. Conclusion: Among women with untreated moderate-to-severe endometriosis pain, the daily burden of pain was extensive, both during menstruation and on nonmenstruating days.

UR - http://www.scopus.com/inward/record.url?scp=85070399279&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070399279&partnerID=8YFLogxK

U2 - 10.1177/2284026519864232

DO - 10.1177/2284026519864232

M3 - Article

AN - SCOPUS:85070399279

VL - 11

SP - 117

EP - 125

JO - Journal of Endometriosis

JF - Journal of Endometriosis

SN - 2035-9969

IS - 3

ER -